Body Pharm Tirzepatide 60 Pen

Body Pharm Tirzepatide 60 Pen: SA Buyer's Guide 2026

The Body Pharm Tirzepatide 60 Pen is a multi-dose injector containing 60 mg of tirzepatide. Its published certificate of analysis lists a 3.0 ml cartridge at roughly 20 mg/ml (batch assay 21.8 mg/ml, purity 99.3%). It delivers four weekly 15 mg doses per pen when administered at standard titration steps. It is sold in South Africa through beskinny.store.

Eli Lilly's Mounjaro is a SAHPRA-registered, prescription-only tirzepatide product. Body Pharm pens are not independently confirmed on the SAHPRA register as of 2026, and South Africa's regulator has warned that unregistered, compounded GLP-1/GIP products are unlawful to manufacture and distribute. That distinction matters: regulatory registration determines which safety data, contraindications, and monitoring protocols apply to the product you're buying.

Key Takeaways

• The 60 mg pen delivers four 15 mg doses and works out cheaper per dose than the 30 mg pen at maintenance level (about R875 versus R1,150 per 15 mg dose on current beskinny.store pricing)
• Tirzepatide is a prescription-only medicine in South Africa; a valid prescription from a registered practitioner is legally required
• The 60 mg pen is designed for users already titrated to 15 mg weekly, not for those starting at 2.5 mg
• Mounjaro is SAHPRA-registered; Body Pharm's regulatory pathway is not independently verified
• Common side effects are gastrointestinal and dose-dependent; slow titration (2.5 mg weekly, stepping up every four weeks) allows adaptation

What Is the Body Pharm Tirzepatide 60mg Pen?

The Body Pharm Tirzepatide 60 Pen is a pre-filled multi-dose injector containing 60 mg of tirzepatide. Its certificate of analysis states a 3.0 ml cartridge at a nominal 20 mg/ml (batch assay 21.8 mg/ml). It delivers four weekly 15 mg doses per pen.

Tirzepatide is the first dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and, separately, for chronic weight management. The dual-receptor design activates two separate incretin pathways at once, and in a head-to-head trial it produced larger glucose and weight reductions than once-weekly semaglutide, a first-generation GLP-1-only drug.

The active ingredient is tirzepatide, the same molecule found in Eli Lilly's Mounjaro (initial U.S. approval 2022) and Zepbound (FDA-approved 8 November 2023). Body Pharm is a separate manufacturer, and the BP pen is not the Lilly KwikPen. The published batch CoA reports 99.3% purity by HPLC, but the pen is not a SAHPRA-registered finished product.

Lilly sells fixed single-strength pens (2.5, 5, 7.5, 10, 12.5, or 15 mg per 0.5 ml), each delivering four once-weekly doses. The Body Pharm 60 mg pen compresses the same 15 mg-per-week ceiling dose into one multi-use cartridge, positioning it at the maintenance end of a titration plan rather than the starter end. That design reduces the number of pens a maintenance-dose user needs to purchase over a month.

Quick spec sheet

• Active ingredient: tirzepatide (dual GIP/GLP-1 agonist)
• Total drug content: 60 mg (label spec 60 mg / 3.0 ml)
• Cartridge concentration: ~20 mg/ml nominal; batch assay 21.8 mg/ml, purity 99.3% (CoA)
• Doses per pen: 4 × 15 mg, once weekly
• Route: subcutaneous injection
• Storage: 2–8 °C, protected from light, sealed; do not freeze (CoA)

For earlier titration steps, the Body Pharm Tirzepatide 30 Pen covers the lower weekly steps. The broader weight loss injections category lists alternatives available in South Africa.

How Tirzepatide Works: GIP + GLP-1 Dual Action

Tirzepatide is a single molecule that activates two incretin receptors at once: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). That dual action pairs two pathways that a single GLP-1 agonist cannot match on its own.

The GLP-1 side performs three functions. It tells the pancreas to release insulin when blood glucose is elevated (so it does not drop sugar in a fasted state the way older insulins can). It suppresses glucagon, the hormone that tells the liver to dump more glucose into the blood. It slows gastric emptying so food leaves the stomach more gradually. Slower emptying is what most users feel as early satiety and reduced appetite, and it's broadly comparable to what a single GLP-1 agonist delivers on its own.

The GIP side is what makes tirzepatide different. GIP agonism enhances insulin secretion in response to nutrients and appears to improve how peripheral tissues handle glucose, layering an additional incretin effect on top of GLP-1. The dual mechanism is documented in the Lilly label, which identifies 15 mg once weekly as the adult maximum dose for type 2 diabetes.

Head-to-head efficacy was tested in the SURPASS trial programme. In SURPASS-2, tirzepatide produced greater reductions in HbA1c and body weight than once-weekly semaglutide 1 mg in adults with type 2 diabetes on metformin. Check the original SURPASS publications for the specific comparator doses and effect sizes before relying on any cross-drug numbers.

For titration up to the 15 mg ceiling that the 60 pen is built around, the lower steps sit in the Body Pharm Tirzepatide 30 Pen. The wider weight loss injections category shows where tirzepatide sits relative to semaglutide-based alternatives in SA.

Tirzepatide for Weight Loss vs Type 2 Diabetes: Key Differences

Tirzepatide is the same molecule in both Mounjaro and Zepbound, but the two brands carry separate FDA approvals for separate indications. Mounjaro is approved for type 2 diabetes (adjunct to diet and exercise). Zepbound is approved for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition, effective 8 November 2023. The regulatory separation exists because the clinical trials, safety monitoring, and labelled outcomes differ between the two indications.

The dosing ladder is identical across both brands: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg once weekly subcutaneously, with 15 mg as the adult maximum. What differs is the labelled outcome the prescriber is treating toward. For type 2 diabetes, the goal is HbA1c reduction and glycaemic control. For obesity, the goal is percentage body-weight reduction. In the SURMOUNT-1 trial, the 15 mg dose produced roughly a 20.9% mean reduction in body weight over 72 weeks — the data underpinning the obesity indication.

Where the Body Pharm pen sits

The Body Pharm Tirzepatide 60 Pen is not Mounjaro and not Zepbound. It is not a branded, SAHPRA-registered finished product carrying either indication. That matters because the FDA-approved indications, contraindications, and safety monitoring requirements attach to the registered brand, not to the active ingredient in isolation.

A prescriber working from your medical history decides whether your clinical picture (T2DM, obesity with comorbidity, or neither) justifies tirzepatide at all, and at which titration step. The regulatory status of the product you're buying affects which prescribing guidelines and safety data your doctor can reference.

For starting titration, the lower steps live on the Body Pharm Tirzepatide 30 Pen. The full weight loss injections range shows how tirzepatide compares with semaglutide options for either indication.

Body Pharm 30mg vs 60mg Pen: Cost-Per-Dose Comparison (2026)

On current beskinny.store pricing, the 60 mg pen works out to roughly R875 per 15 mg dose versus about R1,150 per dose for the 30 mg pen. If you're already titrated to the 15 mg maximum, that's a saving of about R275 each week.

The maths is straightforward once you use the CoA-confirmed cartridge: 60 mg of tirzepatide in 3.0 ml. A 60 mg pen delivers four 15 mg doses; a 30 mg pen delivers two. The 60 mg pen spreads its fixed cost across twice as many doses, lowering the per-dose burden.

Here is the side-by-side at the 15 mg titration step, using prices verified at time of writing.

Spec	Body Pharm 30mg Pen	Body Pharm 60mg Pen
Total tirzepatide	30 mg	60 mg
15 mg doses per pen	2	4
Listed price (ZAR, 2026)	R2,300	R3,500
Cost per 15 mg dose	R1,150	R875
Weeks of supply at 15 mg	2	4

The 60mg pen is the better rand-per-milligram buy at every titration step where you'd otherwise burn through a 30mg pen in two weeks. At lower steps (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg) the calculation shifts because you're drawing smaller volumes and a single pen lasts longer regardless of total fill. A user at 5 mg weekly would draw about 0.25 ml per injection, meaning a 60 mg pen would last 12 weeks instead of four — and the cost advantage disappears.

How we calculated this

We took the 60 mg total content and 3.0 ml cartridge (roughly 20 mg/ml, batch assay 21.8 mg/ml) from the product's published certificate of analysis, and cross-checked the four-dose-per-pen breakdown against the four-dose multi-dose presentation of Lilly's Mounjaro KwikPen. Listed prices are taken from the beskinny.store product pages at the time of writing. Ecommerce prices shift, so confirm the live figure on the 60mg product page and across the broader weight loss injections range before you order.

Dosing Schedule: How to Use the 60mg Pen

The Body Pharm tirzepatide 60 pen delivers four weekly 15 mg doses from a 3.0 ml cartridge (about 20 mg/ml). Each 15 mg dose is roughly 0.75 ml subcutaneously once a week. That dose size matches the maximum maintenance dose on the Lilly Mounjaro label, so the 60mg pen is built for people already titrated up, not for first-time users starting at 2.5 mg. Starting at the highest dose carries a higher risk of gastrointestinal side effects and is not supported by the registered titration protocol.

Standard titration before you reach 15 mg

The Mounjaro label sets a four-week titration ladder: 2.5 mg once weekly for the first four weeks, then 5 mg, then step up by 2.5 mg every four weeks as tolerated, to a maximum of 15 mg once weekly. This gradual escalation lets your body adapt to the drug and gives your prescriber a chance to monitor for side effects before moving to the next dose.

For those at the start of that ladder, the Body Pharm 30 Pen or a lower-strength option from the broader weight loss injections range is the more sensible buy. Drawing small early doses from a 60 mg cartridge wastes the volume. At the 2.5 mg titration step, a 60 mg pen would last 24 weeks, tying up capital and increasing the risk of needle or solution degradation over time.

Injection steps

1. Wash hands and remove the pen from the fridge 15–30 minutes before injecting. The CoA specifies storage at 2–8 °C, protected from light, and warns against freezing.
2. Inspect the solution: the CoA describes it as a colourless to light-yellow solution. Discard if cloudy or containing particles.
3. Attach a fresh pen needle and prime per the manufacturer's instructions.
4. Pinch a clean site on the abdomen, front of the thigh, or back of the upper arm and inject subcutaneously, rotating sites weekly.
5. Hold for the count specified on the device, withdraw, and dispose of the needle in a sharps container.

Diabetes and obesity prescribing can call for different titration speeds and ceiling doses, so follow your prescribing practitioner's written instructions, not generic guidance. This section is not medical advice. Tirzepatide is a prescription-only medicine in South Africa and dosing must be supervised by a registered healthcare practitioner.

SAHPRA Regulatory Status: What S4 Means for SA Buyers

Tirzepatide is a Schedule 4 (S4) medicine in South Africa, which means it is prescription-only and cannot legally be sold, dispensed, or possessed without a valid script from a registered healthcare practitioner. That applies regardless of which pen you buy, where you buy it, or whether the seller calls it "research grade." The classification is the legal mechanism that ensures a qualified doctor assesses your medical suitability before you receive the drug.

The S4 classification sits inside the Medicines and Related Substances Act and is enforced by SAHPRA. In practical terms: a doctor, registered nurse with prescribing rights, or specialist must assess you, write the script, and that script must be dispensed by a pharmacy or clinic operating under the relevant licence. Buying S4 medicine without a prescription is an offence for both the seller and the buyer.

Mounjaro vs Body Pharm: the registration distinction

Mounjaro (Eli Lilly) is the SAHPRA-registered branded tirzepatide product, with the dosing presentation and labelling reflected in the current Lilly regulatory materials. Body Pharm is not listed as a SAHPRA-registered manufacturer of tirzepatide. The Body Pharm Tirzepatide 30 Pen and the 60 pen should be understood as compounded or non-originator product rather than registered branded medicine, and SAHPRA has taken enforcement action against unregistered, compounded GLP-1/GIP medicines. The active ingredient is the same molecule; the regulatory paperwork behind the cartridge is not.

What this means before you buy

Get a consultation and a written script before placing an order, whether you're looking at Body Pharm or any other supplier in the weight loss injections category. Keep the script and the prescriber's contact details on file. A seller offering to ship tirzepatide with no prescription request is a compliance red flag, not a convenience.

Side Effects and Safety Considerations

Tirzepatide's most common adverse effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation, and decreased appetite, according to the Mounjaro prescribing information. These effects are typically dose-dependent and most pronounced during the first weeks after a dose escalation. The registered titration starts at 2.5 mg weekly and steps up no faster than every four weeks, giving your gastrointestinal system time to adapt to the drug's effects on gastric emptying.

The Mounjaro label carries a boxed warning for thyroid C-cell tumours, based on rodent studies, with the drug contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The human relevance of the rodent finding has not been determined.

Other serious risks listed in the prescribing information include acute pancreatitis, acute kidney injury (usually secondary to dehydration from vomiting or diarrhoea), gallbladder disease, and severe hypersensitivity reactions. These are less common but require medical supervision to detect early.

Hypoglycaemia and drug interactions

Tirzepatide on its own carries a low hypoglycaemia risk. The risk rises when it is combined with insulin or a sulfonylurea, and the label recommends reducing the dose of the insulin or sulfonylurea at initiation.

Tirzepatide can also reduce the effectiveness of oral contraceptives, so the label advises switching to a non-oral method or adding a barrier method for four weeks after starting and after each dose increase. These interactions occur because tirzepatide alters glucose handling and slows gastric emptying, which can affect the absorption of other drugs.

None of this replaces a proper consultation. A prescriber needs your full medical history, current medication list, and ideally recent bloods before signing off on either the Body Pharm Tirzepatide 30 Pen or the 60 pen, or any other product in the broader weight loss injections category.

How the 60mg Pen Compares to Other Tirzepatide Options in SA

For buyers already stabilised at 15 mg weekly, the Body Pharm Tirzepatide 60 Pen is the lowest cost-per-dose tirzepatide option on beskinny.store. Its four 15 mg doses spread the pen price across a full month of maintenance therapy.

For anyone still titrating up from 2.5 mg or 5 mg, the Body Pharm Tirzepatide 30 Pen makes more sense. Drawing small early doses from a 60 mg cartridge wastes volume, and at the 2.5 mg step the pen would last 24 weeks, tying up capital and raising the risk of degradation over time.

Two other in-house options are worth considering. The HD Labs Tirzepatide 30 Vial is a same-molecule alternative in a self-mix vial format, useful if you prefer a second-source brand during titration. The HD Tirsema 44 Pen is a different proposition entirely: a tirzepatide-plus-semaglutide combination whose combined use has not been studied in published human trials and is not SAHPRA-registered — not directly comparable to a pure tirzepatide pen.

The registered Lilly product, Mounjaro, remains the SAHPRA-route reference point for prescribing standards and is dosed identically at 2.5–15 mg once weekly. Its registration means your prescriber can reference the full FDA and SAHPRA dossier when making dosing decisions.

The broader weight loss injections category page lists the full range if you want to cross-shop GLP-1 monotherapy against dual-agonist options before committing.

Frequently Asked Questions

How many injections are in the Body Pharm Tirzepatide 60mg pen?

The Body Pharm Tirzepatide 60 Pen contains four 15 mg doses, derived from its 60 mg total drug content in a 3.0 ml cartridge. That matches the four-dose multi-dose pen architecture in the Lilly reference product, where each KwikPen delivers four weekly doses. One pen covers a full four-week cycle at the 15 mg maintenance dose.

What is the cost per dose of the 60mg pen vs the 30mg pen?

At current pricing the 60 mg pen produces a lower cost-per-dose than the Body Pharm Tirzepatide 30 Pen for buyers already at the 15 mg maintenance level — roughly R875 per dose versus about R1,150, because the pen price is divided across four 15 mg doses rather than two. Live rand pricing should be confirmed on the product pages at purchase, since ecommerce pricing changes. At lower titration steps, the cost advantage disappears because you draw smaller volumes and the 60 mg pen lasts longer.

Do I need a prescription to buy tirzepatide in South Africa?

Yes. Tirzepatide is a Schedule 4, prescription-only medicine, meaning a valid prescription from a registered medical practitioner is legally required before dispensing. Compounded or research-grade tirzepatide pens are not automatically SAHPRA-registered, so ask your prescriber to confirm regulatory status before purchase. A legitimate prescriber will always require a consultation and will not dispense without a documented medical assessment.

What is the difference between Mounjaro and the Body Pharm tirzepatide pen?

Mounjaro is the Eli Lilly-registered tirzepatide product with SAHPRA-route regulatory standing and a formal label covering type 2 diabetes. The Body Pharm pen contains the same molecule but does not have a verified SAHPRA registration entry. The two are not regulatory equivalents even though the active ingredient and weekly dosing range (2.5–15 mg) are the same. Mounjaro's registration means its safety data, contraindications, and prescribing guidelines have undergone SAHPRA review; Body Pharm's regulatory pathway has not been independently verified.

How long will one 60mg pen last at the standard weekly dose?

One 60 mg pen lasts four weeks at the 15 mg once-weekly maintenance dose, since each pen delivers four 15 mg injections. For users still titrating at 2.5, 5, 7.5, 10, or 12.5 mg, the 60 mg pen is not the efficient choice; the 30 mg pen or a category cross-shop on weight loss injections is more appropriate. At 5 mg weekly, a 60 mg pen would last 12 weeks and tie up capital unnecessarily.

Can tirzepatide be used for weight loss if I don't have type 2 diabetes?

Yes, internationally. Tirzepatide is FDA-approved as Zepbound for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition, effective 8 November 2023. In South Africa, the SAHPRA-registered indication is type 2 diabetes via Mounjaro. Off-label weight-loss prescribing is a clinical decision your prescriber must make and document, weighing the evidence against your individual medical history.

Next Steps

Confirm your current tirzepatide dose with your prescriber before ordering. If you're at 15 mg weekly maintenance, request a written script and compare the Body Pharm Tirzepatide 60 Pen against the 30 mg option on cost-per-dose. If you're still titrating, start with the 30 mg pen or browse the full weight loss injections range to find the right entry point for your stage. Keep your prescriber's contact details and a copy of your script on file.

References

1. Mounjaro (tirzepatide) injection — full prescribing information. DailyMed, U.S. National Library of Medicine, 2024.
2. FDA Approves New Medication for Chronic Weight Management (Zepbound / tirzepatide). U.S. Food and Drug Administration, 2023.
3. Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine, 2021.
4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
5. SAHPRA and the SAPC Crack Down on Unlawful Manufacturing of Unregistered GLP-1/GIP Medicines. South African Health Products Regulatory Authority, 2026.
6. Body Pharm Tirzepatide 60 Pen — Certificate of Analysis (batch C-Ti60-3.0-20251010). Body Pharm, 2025.